Helmet noninvasive ventilation for COVID-19 patients (Helmet-COVID): statistical analysis plan for a randomized controlled trial

Yaseen Arabi, Sara Aldekhyl, Saad Al Qahtani, Hasan M Al-Dorzi, Sheryl Ann Abdukahil, Jesna Jose, Mohammad Khulaif Al Harbi, Husain Al Haji, Mohammed Al Mutairi, Omar Al Zumai, Eman Al Qasim, Wedyan Al Wehaibi, Mohammed Alshahrani, Talal Albrahim, Ahmed Mady, Ali Al Bshabshe, Zohair Al Aseri, Zainab Al Duhailib, Ayman Kharaba, Rakan Alqahtani, Haifa Algethamy, Omar Alfaris, Omar Alnafel, Abdulrahman A Al-Fares, Haytham Tlayjeh, Yaseen Arabi, Sara Aldekhyl, Saad Al Qahtani, Hasan M Al-Dorzi, Sheryl Ann Abdukahil, Jesna Jose, Mohammad Khulaif Al Harbi, Husain Al Haji, Mohammed Al Mutairi, Omar Al Zumai, Eman Al Qasim, Wedyan Al Wehaibi, Mohammed Alshahrani, Talal Albrahim, Ahmed Mady, Ali Al Bshabshe, Zohair Al Aseri, Zainab Al Duhailib, Ayman Kharaba, Rakan Alqahtani, Haifa Algethamy, Omar Alfaris, Omar Alnafel, Abdulrahman A Al-Fares, Haytham Tlayjeh

Abstract

Background: Noninvasive respiratory support is frequently needed for patients with acute hypoxemic respiratory failure due to coronavirus disease 19 (COVID-19). Helmet noninvasive ventilation has multiple advantages over other oxygen support modalities but data about effectiveness are limited.

Methods: In this multicenter randomized trial of helmet noninvasive ventilation for COVID-19 patients, 320 adult ICU patients (aged ≥14 years or as per local standards) with suspected or confirmed COVID-19 and acute hypoxemic respiratory failure (ratio of arterial oxygen partial pressure to fraction of inspired oxygen < 200 despite supplemental oxygen with a partial/non-rebreathing mask at a flow rate of 10 L/min or higher) will be randomized to helmet noninvasive ventilation with usual care or usual care alone, which may include mask noninvasive ventilation, high-flow nasal oxygen, or standard oxygen therapy. The primary outcome is death from any cause within 28 days after randomization. The trial has 80% power to detect a 15% absolute risk reduction in 28-day mortality from 40 to 25%. The primary outcome will be compared between the helmet and usual care group in the intention-to-treat using the chi-square test. Results will be reported as relative risk and 95% confidence interval. The first patient was enrolled on February 8, 2021. As of August 1, 2021, 252 patients have been enrolled from 7 centers in Saudi Arabia and Kuwait.

Discussion: We developed a detailed statistical analysis plan to guide the analysis of the Helmet-COVID trial, which is expected to conclude enrollment in November 2021.

Trial registration: ClinicalTrials.gov NCT04477668 . Registered on July 20, 2020.

Keywords: COVID-19; Helmet noninvasive ventilation; Noninvasive ventilation; Statistical analysis plan.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT flow diagram

References

    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell COVID-19 Research Consortium. Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. Jama. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775.
    1. Cabrini L, Landoni G, Zangrillo A. Minimise nosocomial spread of 2019-nCoV when treating acute respiratory failure. Lancet. 2020;395(10225):685. doi: 10.1016/S0140-6736(20)30359-7.
    1. Amirfarzan H, Cereda M, Gaulton T, Leissner K, Cortegiani A, Schumann R, et al. Use of helmet CPAP in COVID-19: a practical review. Pulmonology. 2021;S2531-0437(21):00040–00044.
    1. Brambilla AM, Aliberti S, Prina E, Nicoli F, Del Forno M, Nava S, et al. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia. Intensive Care Med. 2014;40(7):942–949. doi: 10.1007/s00134-014-3325-5.
    1. Cosentini R, Brambilla AM, Aliberti S, Bignamini A, Nava S, Maffei A, Martinotti R, Tarsia P, Monzani V, Pelosi P. Helmet continuous positive airway pressure vs oxygen therapy to improve oxygenation in community-acquired pneumonia: a randomized, controlled trial. Chest. 2010;138(1):114–120. doi: 10.1378/chest.09-2290.
    1. Patel BK, Wolfe KS, Pohlman AS, Hall JB, Kress JP. Effect of noninvasive ventilation delivered by helmet vs face mask on the rate of endotracheal intubation in patients with acute respiratory distress syndrome: a randomized clinical trial. JAMA. 2016;315(22):2435–2441. doi: 10.1001/jama.2016.6338.
    1. Foti G, Sangalli F, Berra L, Sironi S, Cazzaniga M, Rossi G, et al. Is helmet CPAP first line pre-hospital treatment of presumed severe acute pulmonary edema? Intensive care medicine. 2009;35(4):656–662. doi: 10.1007/s00134-008-1354-7.
    1. Squadrone V, Coha M, Cerutti E, Schellino M, Biolino P, Occella P, et al. Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. Jama. 2005;293(5):589. doi: 10.1001/jama.293.5.589.
    1. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochwerg B, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure: a systematic review and meta-analysis. Jama. 2020;324(1):57–67. doi: 10.1001/jama.2020.9524.
    1. Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID-19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA. 2021;325(17):1731-43. 10.1001/jama.2021.4682.
    1. Arabi YM, Tlayjeh H, Aldekhyl S, Al-Dorzi HM, Abdukahil SA, Al Harbi MK, et al. Helmet non-invasive ventilation for COVID-19 patients (Helmet-COVID): study protocol for a multicentre randomised controlled trial. BMJ Open. 2021;11(8):e052169. doi: 10.1136/bmjopen-2021-052169.
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c869. doi: 10.1136/bmj.c869.
    1. Schulz KF, Altman DG, Moher D, Group C CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340(mar23 1):c332. doi: 10.1136/bmj.c332.
    1. Edsberg LE, Black JM, Goldberg M, McNichol L, Moore L, Sieggreen M. Revised national pressure ulcer advisory panel pressure injury staging system: revised pressure injury staging system. Journal of Wound, Ostomy, and Continence Nursing. 2016;43(6):585.
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B (Methodol) 1995;57(1):289–300.
    1. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80(3):557–572. doi: 10.1093/biomet/80.3.557.
    1. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res. 2011;20(10):1727–1736. doi: 10.1007/s11136-011-9903-x.
    1. EQ-5D-5L Crosswalk Index Value Calculator. Available at: 2021.
    1. Muruganandan S, Azzopardi M, Fitzgerald DB, Shrestha R, Kwan BCH, Lam DCL, de Chaneet CC, Rashid Ali MRS, Yap E, Tobin CL, Garske LA, Nguyen PT, Stanley C, Popowicz ND, Kosky C, Thomas R, Read CA, Budgeon CA, Feller-Kopman D, Maskell NA, Murray K, Lee YCG. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671–680. doi: 10.1016/S2213-2600(18)30288-1.
    1. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549–556. doi: 10.2307/2530245.
    1. Liu Q, Gao Y, Chen R, Cheng Z. Noninvasive ventilation with helmet versus control strategy in patients with acute respiratory failure: a systematic review and meta-analysis of controlled studies. Critical Care. 2016;20(1).
    1. Luo Y, Luo Y, Li Y, Zhou L, Zhu Z, Chen Y, et al. Helmet CPAP versus oxygen therapy in hypoxemic acute respiratory failure: a meta-analysis of randomized controlled trials. Yonsei Med J. 2016;57(4):936–941. doi: 10.3349/ymj.2016.57.4.936.
    1. Tverring J, Åkesson A, Nielsen N. Helmet continuous positive airway pressure versus high-flow nasal cannula in COVID-19: a pragmatic randomised clinical trial (COVID HELMET) Trials. 2020;21(1):1–10. doi: 10.1186/s13063-020-04863-5.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren